Inventor · disambiguated record
Michael Caramian Cochran
Also filed as: COCHRAN MICHAEL · COCHRAN MICHAEL C · COCHRAN Michael Caramian
36 granted patents·22 pending applications·389 citations·filing 2016–2025
98Inventor score
Files withAVIDITY BIOSCIENCES INC51GLAXOSMITHKLINE BIOLOGICALS SA5AVIDITY BIOSCIENCES LLC1LILLY CO ELI1
Top patents by PatentIndex Score
58 records- 0198US12064483B2Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2022·Granted Aug 20, 2024·19 cites·24 claims
- 0298US11446387B2Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Sep 20, 2022·8 cites·14 claims
- 0398US11400163B2Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2021·Granted Aug 2, 2022·26 cites·22 claims
- 0498US11311627B1Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2021·Granted Apr 26, 2022·28 cites·24 claims
- 0598US11253607B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2020·Granted Feb 22, 2022·7 cites·23 claims
- 0698US11246941B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Feb 15, 2022·7 cites·23 claims
- 0798US11179472B2Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2018·Granted Nov 23, 2021·35 cites·25 claims
- 0898US10994020B2Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2018·Granted May 4, 2021·32 cites·24 claims
- 0998US10881743B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2019·Granted Jan 5, 2021·55 cites·16 claims
- 1098US10787519B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Sep 29, 2020·19 cites·17 claims
- 1198US10550188B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Feb 4, 2020·80 cites·13 claims
- 1297US11707532B2Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Jul 25, 2023·3 cites·14 claims
- 1397US11576980B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Feb 14, 2023·6 cites·23 claims
- 1497US11497814B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Nov 15, 2022·3 cites·30 claims
- 1597US10487149B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Nov 26, 2019·21 cites·18 claims
- 1696US11583591B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Feb 21, 2023·2 cites·14 claims
- 1796US11554176B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Jan 17, 2023·2 cites·16 claims
- 1896US11110180B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Sep 7, 2021·19 cites·20 claims
- 1995US12427202B2Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2023·Granted Sep 30, 2025·1 cites·9 claims
- 2095US10800848B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Oct 13, 2020·7 cites·16 claims
- 2194US11872287B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Jan 16, 2024·1 cites·17 claims
- 2293US12006499B2Una amidites and uses thereofAVIDITY BIOSCIENCES INC·Filed 2020·Granted Jun 11, 2024·2 cites·8 claims
- 2393US11364302B1Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2021·Granted Jun 21, 2022·2 cites·20 claims
- 2491US2024358736A1Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 2589US12359202B2Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skippingAVIDITY BIOSCIENCES INC·Filed 2024·Granted Jul 15, 2025·1 cites·21 claims
- 2689US12071621B2Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skippingAVIDITY BIOSCIENCES INC·Filed 2023·Granted Aug 27, 2024·1 cites·21 claims
- 2787US2025381285A1Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 2886US12263224B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Apr 1, 2025·0 cites·15 claims
- 2985US2023047754A1Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3084US11578090B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2020·Granted Feb 14, 2023·1 cites·1 claims
- 3184US2025381286A1Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 3282US2025296946A1Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 3381US12365704B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2022·Granted Jul 22, 2025·0 cites·13 claims
- 3481US11712478B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Aug 1, 2023·0 cites·13 claims
- 3579US12351637B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2021·Granted Jul 8, 2025·0 cites·15 claims
- 3679US12234290B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2021·Granted Feb 25, 2025·0 cites·23 claims
- 3779US2024301419A1Una amidites and uses thereofAVIDITY BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 3878US2025161344A1Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 3978US2025195676A1Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 4078US2025171544A1Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 4175US2020123261A1Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 4274US12364769B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2021·Granted Jul 22, 2025·0 cites·12 claims
- 4372US10646566B2Compositions and usesGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2016·Granted May 12, 2020·1 cites·16 claims
- 4472US2025152726A1Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 4570US2022144833A1Imidazoquinoline derivatives and their use in therapyGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Application pending·0 cites
- 4670US2022144865A1Imidazoquinoline derivatives and their use in therapyGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Application pending·0 cites
- 4769US2017281795A1Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES LLC·Filed 2017·Application pending·0 cites
- 4869US2025170260A1Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 4968US2025121085A1Antibody-oligonucleotide conjugate compositions and methods of inducing dmd exon 45 skippingAVIDITY BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 5062US11207404B2Compositions and usesGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2020·Granted Dec 28, 2021·0 cites·6 claims
Showing the top 50 of 58 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Michael Caramian Cochran files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →